Overview
Updated 14 Jul 2026
Meghan Sise, MD, is Director of Onconephrology, Massachusetts General Hospital. The public record shows 272 publications with 9,785 citations (h-index 46), centered on Hepatitis C virus research, Cancer Immunotherapy and Biomarkers, Acute Kidney Injury Research. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 8 companies, 4 NIH-funded awards (2018–2026).
- Most recent indexed publication: 2025 · bioRxiv
- Top research focus: Hepatitis C virus research
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 17 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 122.
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- Infliximab for Immune Checkpoint Inhibitor Associated AKI
Sponsor: Massachusetts General Hospital
InvestigatorPhase 4Not, yet, recruitingNCT07683975 - Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease
Sponsor: Angion Biomedica Corp
InvestigatorPhase 2UnknownNCT04939116 - Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance
Sponsor: Columbia University
InvestigatorPhase 2RecruitingNCT04614558
Industry payments
Updated 14 Jul 2026
8 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Otsuka Pharmaceutical Development & Commercialization, Inc.Program year20257 payments$15,513openpaymentsdata.cms.gov ↗
- Vertex Pharmaceuticals IncorporatedProgram year20252 payments
- Travere Therapeutics, Inc.Program year20252 payments
NIH funding
Updated 14 Jul 2026
4 NIH research awards on record, funded 2018–2026 per NIH RePORTER. The latest:
- Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer
Massachusetts General Hospital
FY2026$647,716R01DK130839 - Pilot Randomized Clinical Trial of Glucocorticoid-Sparing Immunosuppressive Treatments for Immune Checkpoint Inhibitor-Associated AKI
Massachusetts General Hospital
FY2026$312,324R01DK144161 - Rapid Diagnosis and Treatment Response Phenotyping of Immune Checkpoint Inhibitor-Associated Acute Interstitial Nephritis
Yale University
FY2025$719,851R01DK140717
Congress activity
Updated 14 Jul 2026
9 congress contributions (2018–2025) across ASCO, ASH per OpenAlex. The most recent:
- Detection of immune-related adverse events among hospitalized patients using large language models.
ASCO Annual Meeting
ASCO2024Co-author - Isatuximab for Treatment of Monoclonal Gammopathy of Renal Significance (MGRS) - Results from a Prospective Phase 2 Trial
ASH Annual Meeting
ASH2024Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Large Discordance between Creatinine-Based and Cystatin C-Based eGFRs is Associated with Falls, Hospitalizations, and Death in Older Adults.
Clinical journal of the American Society of Nephrology
2024 - AKI treated with kidney replacement therapy in critically Ill allogeneic hematopoietic stem cell transplant recipients.
Bone marrow transplantation
2024
Most-cited worksby citation count (OpenAlex)
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
Suite 302, 165 Cambridge Street, Boston, MA 02114
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- MD
Columbia University College of Physicians & Surgeons
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →massgeneral.org ↗ - MS
Patient-Oriented Research, Columbia University Mailman School of Public Health
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onconephrology.mgh.harvard.edu ↗ - BS
University of Notre Dame, summa cum laude
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onconephrology.mgh.harvard.edu ↗ - Board Certified
Internal Medicine (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →massgeneral.org ↗ - Residency
Internal Medicine, Massachusetts General Hospital
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onconephrology.mgh.harvard.edu ↗ - Fellowship
Nephrology, Columbia University Medical Center / New York Presbyterian Hospital
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onconephrology.mgh.harvard.edu ↗ - Research Fellowship
Nephrology, Massachusetts General Hospital (under Ravi Thadhani and Raymond Chung)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onconephrology.mgh.harvard.edu ↗
Editorial & leadership rolesjournal and society appointments
- Associate Editor
NEJM Clinician (New England Journal of Medicine)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clinician.nejm.org ↗
Awards & honorshonors on the public record
- Janeway Prize (highest achievement/abilities at graduation)
Columbia University College of Physicians & Surgeons
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onconephrology.mgh.harvard.edu ↗ - Claflin Distinguished Scholar Award
Massachusetts General Hospital
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onconephrology.mgh.harvard.edu ↗
Secondary affiliationsappointments beyond the home institution
- Principal Investigator
MGH Onconephrology research program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onconephrology.mgh.harvard.edu ↗
Media & interviewspress, podcasts and appearances
- Contributor
Mass General Advances in Motion (multiple feature articles on AKI/CAR-T therapy, COVID-19 and nephrology, Medical Grand Rounds)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →advances.massgeneral.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by otherswhere others cite or feature them
- LinkedIn
linkedin.com/posts/reachmd_nephrology-fsgs-cme-activity-7382176791139942401-EUfk
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Richardson, MD
Harvard University
- 2,062
- publications
- 172
- h-index
- 17
- trials
Pasi Janne, MD, PhD
Harvard University
- 2,385
- publications
- 163
- h-index
- 15
- trials
Steven Greenberg, MD
Harvard University
- 954
- publications
- 144
- h-index
- 9
- trials
David Scadden, MD
Harvard University
- 665
- publications
- 124
- h-index
- 4
- trials